Trial Name: SWOG E5597
Phase III Chemoprevention Trial of Selenium
Supplementation in Persons with Resected Stage I, Non-Small Cell
Lung Cancer
Trial
Description:
Chemoprevention therapy is the use of certain
drugs to try to prevent the development or recurrence of cancer.
The purpose of this study is to determine the effectiveness of
selenium in preventing the development of second primary lung
tumors in patients who have undergone surgery to remove stage I
non-small cell lung cancer.
Treatment
Plan:
Patients will be randomized to one of two
treatment arms:
1. Arm 1 - selenium yeast tablet (one tablet
daily for 4 years)
2. Arm 2 - placebo yeast tablet ( one tablet daily for 4 years)
Patients:
- At least 18 years
old
- At least 6 months, but no more than 3 years, since surgery to
remove stage I non-small cell lung cancer
- No evidence of lung cancer after
surgery
- No previous chemotherapy or radiation therapy for lung
cancer
- Lab tests, a current physical and medical history must meet study
specific criteria
This is a brief overview
of this clinical trial and only selected eligibility criteria are
listed. If you are interested in receiving more information to see
if you are eligible to participate in this study, please
contact:
Mercy General
Hospital
Rhoda Pineda at (916) 453-4651, or e-mail
rpineda@chw.edu
Mercy San Juan
Medical Center
Margaret Murphy at
(916) 537-5109, or e-mail margaret.murphy2@chw.edu
